Drugs / VXA-G1.1-NN
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials · 1 met primary | ||||||
| Phase 1 | NCT06944717 | Mar 2025 → May 2026 overdue | norovirus infectious disease | Vaxart | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07254728 | Oct 2023 → Dec 2024 | norovirus infectious disease | Vaxart | Completed | No outcome recorded |
| Phase 1 | NCT05213728 | Jan → Feb 2022 | norovirus infectious disease | Vaxart | Completed | No outcome recorded |
| Phase 1 | NCT03897309 | Mar 2019 → Jan 2021 | norovirus infectious disease | Vaxart | Completed | No outcome recorded |
| Phase 1 | NCT02868073 | Jul → Oct 2016 | norovirus infectious disease | Vaxart | Completed | Met primary |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05626803 | Jan → Oct 2023 | norovirus infectious disease | Vaxart | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT05212168 Comparator | Dec 2021 → Apr 2023 | norovirus infectious disease | Vaxart | Completed | No outcome recorded |
| Phase 1/2 | NCT04875676 Comparator | Apr → Oct 2021 | norovirus infectious disease | Vaxart | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXA-G1.1-NN | “This study is designed to evaluate the safety and immunogenicity of two monovalent Norovirus (NoV) oral tableted vaccine candidates, VXA-G1.1-NN and VXA-GII.4-NS...” NCT05626803 ↗ |
| Known as | Vaxart Norovirus vaccine | “This is a Phase 2b randomized, double-blind, placebo-controlled vaccination and challenge study to assess the protective efficacy of the Vaxart Norovirus vaccine (VXA-G1.1-NN).” NCT05212168 ↗ |
| Modality | Vaccine | “Adenoviral-vector Based Norovirus Vaccine” NCT02868073 ↗ |
| Route | Oral | “orally administered VXA-G1.1-NN” NCT02868073 ↗ |